Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Journal for Immunotherapy of Cancer|July 24, 2014
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastomaMinghui Li, Aaron R Bolduc, Md Nasrul Hoda, et al.Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.Cancer Gene Therapy|January 7, 2021
Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcomaSalah-Eddine Lamhamedi-Cherradi, Sana Mohiuddin, Dhruva K Mishra, et al.Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.Leukemia|July 14, 2023
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapiesBranko Cuglievan, Jeremy Connors, Jiasen He, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 9, 2022
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyMatthew Barth, Ana C Xavier, Saro Armenian, et al.Cancers|July 8, 2020
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive BiomarkersHesham M Amin, Ajaykumar C Morani, Najat C Daw, et al.Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2025
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyHiroto Inaba, David Teachey, Colleen Annesley, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.Pageof 5